TargetMol

RS-93522

Product Code:
 
TAR-T28618
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28618-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28618-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28618-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
RS-93522 is an antagonist of calcium channel. RS-93522 had the additional property of inhibiting phosphodiesterase activity in myocardial homogenates (IC50 = 1.6 x 10(-5)M), the potency and efficacy of phosphodiesterase inhibition was similar to that for milrinone in the same system. As expected of Ca channel antagonists, it has a negative inotropic effect on cultured myocardial cells.
CAS:
104060-12-0
Formula:
C27H30N2O9
Molecular Weight:
526.542
Purity:
0.98
SMILES:
COC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OCCc1ccc(OCC(O)CO)cc1

References

1. Fu RC, Whatley JL, Fleitman JS. Intranasal delivery of RS-93522, a dihydropyridine-type calcium-channel antagonist. Pharm Res. 1991 Jan;8(1):134-5. PubMed PMID: 2014202. 2. Kern JR, Lokensgard DM, Yang TY. Chromatographic separation of the diastereomers of a dihydropyridine-type calcium channel antagonist as the bis-3,5-dinitrobenzoates. J Chromatogr. 1988 Dec 21;457:309-16. PubMed PMID: 3243886. 3. Lidgate DM, Felgner PL, Fleitman JS, Whatley J, Fu RC. In vitro and in vivo studies evaluating a liposome system for drug solubilization. Pharm Res. 1988 Dec;5(12):759-64. PubMed PMID: 3247285. 4. Marsh JD, Dionne MA, Chiu M, Smith TW. A dihydropyridine calcium channel blocker with phosphodiesterase inhibitory activity: effects on cultured vascular smooth muscle and cultured heart cells. J Mol Cell Cardiol. 1988 Dec;20(12):1141-50. PubMed PMID: 2470909.